Cargando…

Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human

Receptor occupancy (RO) is a translational biomarker for assessing drug efficacy and safety. We aimed to apply a physiologically based pharmacokinetic (PBPK) modeling approach to predict the brain dopamine D2 RO time profiles of antipsychotics. Clozapine and risperidone were modeled together with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Yin Cheong, Centanni, Maddalena, de Lange, Elizabeth C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Physiologically Based Pharmacokinetic Modeling
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590357/ https://www.ncbi.nlm.nih.gov/pubmed/30676661 http://dx.doi.org/10.1002/jcph.1365

Ejemplares similares

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib
por: Adiwidjaja, Jeffry, et al.
Publicado: (2022)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin
por: Butrovich, Morgan A., et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition
por: Long, Tao, et al.
Publicado: (2021)

Serum concentrations of antidepressants, antipsychotics, and antiepileptics over the bariatric surgery procedure
por: Wallerstedt, Susanna M., et al.
Publicado: (2021)

PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human
por: Campbell, Jerry L., et al.
Publicado: (2016)

A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS‐986231 in Healthy Volunteers
por: Cowart, Douglas, et al.
Publicado: (2019)

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
por: Kirschbrown, Whitney P., et al.
Publicado: (2018)

Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent
por: Nguyen, Ashley, et al.
Publicado: (2021)

An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2020)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers*
por: Zecca, Ernesto, et al.
Publicado: (2015)

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting
por: Shannon, Richard J, et al.
Publicado: (2014)

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
por: Størset, Elisabet, et al.
Publicado: (2014)

Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians
por: Hasunuma, Tomoko, et al.
Publicado: (2016)

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers
por: Chairat, Kalayanee, et al.
Publicado: (2016)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation
por: Kloprogge, Frank, et al.
Publicado: (2015)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
por: Lee, Yoon Jung, et al.
Publicado: (2016)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Single‐dose pharmacokinetics of co‐crystal of tramadol–celecoxib: Results of a four‐way randomized open‐label phase I clinical trial in healthy subjects
por: Videla, Sebastián, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial
por: Videla, Sebastián, et al.
Publicado: (2017)

Risk factors contributing to a low darunavir plasma concentration
por: Daskapan, Alper, et al.
Publicado: (2017)

The effects of advanced age and serum α(1)‐acid glycoprotein on docetaxel unbound exposure and dose‐limiting toxicity in cancer patients
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2017)

ADAM, a hands‐on patient simulator for teaching principles of drug disposition and compartmental pharmacokinetics
por: Zuna, Ines, et al.
Publicado: (2017)

Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting
por: Gilmore, James, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g4n9u33rs4vbtgb6u60td6fhnc